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Iodixanol vs ioxaglate for
preventing contrast nephropathy:
Who is winner ?
Kidney International (2007) 71, 828. doi:10.1038/sj.ki.5002211
To the Editor: We read with interest the article by Dr P Liss
et al.1 They reported results contrary to that of our
RECOVER study and recent meta-analysis, which revealed
a lower incidence of contrast induced nephropathy (CIN) in
iodixanol than in ioxaglate users.2,3 We have some comments
and queries.
First, this different result may be attributed to the study
scheme itself. Our RECOVER study was a prospective
randomized controlled trial, but Dr P Liss’s was a retro-
spective study with many compounding factors influencing
the results.
Second, they did not present the most important risk
factors of CIN, basal serum creatinine and contrast dose.
They only briefly mentioned the data of 14% of patients
(8100 among 57 925 patients) and these data were recorded
in only a restricted period of 2005. They just reported the
mean and median values without depicting P-values.
Third, and most importantly, baseline characteristics of
the two groups were significantly different. The risk factors of
CIN – age, proportion of patients with diabetes, patients with
STEMI, unstable angina, proportion of patients receiving
PCI, previous renal failure, and previous dialysis – were
significantly different between the two groups.
We think that previous renal failure and previous dialysis
were the most critical determinants of developing CIN and
factors affecting clinical outcomes – re-hospitalization with a
renal failure and start of dialysis after angiography. These
were much more in the iodixanol group, which, we think,
might influence the result of poorer clinical outcomes of
iodixanol users.
We completely disagree with Dr P Liss et al. We think that
larger-scale long-term clinical data are necessary for solving
the important issue of which contrast medium is renal
protective.
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We thank Jo et al.1 for their thoughtful comments on our
manuscript. Indeed the outcome of our study sheds new
light on to the debate, which class of contrast media may
be best for avoiding renal failure.
Jo et al. feel that our study design, that is being
retrospective, may partly explain the outcome. Of course
the value of a study critically depends upon the design.
Optimal outcome can be expected for prospective rando-
mized studies with very large sample sizes. In this sense, all
studies focussing on contrast media and kidney function in
humans must be considered with caution: for instance, the
RECOVER2 study by Jo and co-workers, and the NEPH-
RIC3 study by Aspelin and co-workers were prospective
studies with 129 and 300 patients, respectively. In the study
discussed here,4 57 925 patients were evaluated on a
retrospective basis. Retrospective studies are widely in
use and provide valuable insight, such as the effectiveness
of vaccinations, only to mention one.
Jo et al. point out that values for basal creatinine and
the dose of contrast media were not available for all
patients. We agree that this is a drawback. Only since
2005 does the register include these data. Thus, we
analyzed these data in 8100 patients. As stated in the
publication, there were no significant differences in
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volume given (iodixanol – 138789 ml vs iogloxate –
1477105 ml; the median values were 110 ml and 120 ml,
respectively). Moreover, the baseline creatinine values are
comparable (iodixanol – 91754 lmol/l vs ioxaglate –
100756 lmol/l; median values: 83 lmol/l vs 92 lmol/l,
respectively). Jo et al. are concerned that the P-values were
not provided for these differences. Our statement that the
differences were not statistically significant may have
escaped their attention; P was greater than 0.05. Moreover,
the iodixanol treated patients were those that received
slightly less contrast media and had slightly lower
baseline creatinine values. Thus, the disadvantageous
effect of giving iodixanol described in our study is not
likely to be explained by the iodixanol-treated patients
receiving greater volumes or having higher baseline
creatinine levels.
Jo et al. feel that the most important restriction of the
discussed study is the difference in risk factors. Due to the
very large patient numbers, even very minor differences
(for instance a difference in age of 64.8710.7 years vs
64.4711.1 years) become highly significant. This under-
scores the power of a large sample size. However, we wish
to point out that all significant differences in risk factors
were compensated for in the calculation of the odds ratio
(Table 4 of the study). The odds ratio calculation indicated
that iodixanol treatment is roughly twice as likely to cause
renal failure (Po0.001).
In particular, Jo et al. are concerned about the higher
incidence of previous renal failure and previous dialysis, which
was more often encountered in the iodixanol treated group.
Although these differences were also compensated for, we
made a separate analysis for only these patients who had
experienced renal failure previously or had required
dialysis before. The outcome was as for the entire group:
renal failure in high-risk patients who previously had renal
failure or needed dialysis was much more likely to occur if
iodixanol was used instead of ioxaglate (Table 4 and Figure 1
of the study).
What we feel is particularly convincing is what
happened to the hospital that switched contrast medium
from ioxaglate to iodixanol (Figure 1 of the study). Renal
failure more than doubled. However, all this evidence does
not preclude the necessity to perform a large randomized
prospective study to solve the question as to which contrast
medium is best for the kidney, we agree.
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Osseous and myeloid metaplasia
in a failed renal allograft
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To the Editor Tousignant et al.1 recently reported a case
of osseous metaplasia in a renal transplant with chro-
nic rejection. A second case of renal allograft osseous
metaplasia is found in the literature.2 We would like to
report a third case, the first to display foci of myeloid
metaplasia, in an end-stage kidney transplant.
A 28-year-old woman with end-stage kidney disease
secondary to diabetic nephropathy underwent living-donor
renal transplantation in 1999. The transplant functioned well
until 2000 when creatinine began to rise and renal function
deteriorated progressively. Repeated biopsies showed epi-
sodes of acute cellular rejection, calcineurin inhibitor toxicity,
and interstitial fibrosis and tubular atrophy. Peritoneal
dialysis was started in 2004. Transplant nephrectomy was
performed 7 years post-transplant for persistent anemia and
failure to thrive.
The transplant showed widespread hemorrhage with
foci of hard material. Light microscopy revealed an
extensively scarred renal parenchyma with patchy necrosis
and negligible residual functional tissue. Arteries showed
Figure 1 | Renal allograft showing osseous metaplasia with
intertrabecular loose adipose tissue containing hematopoietic
lineage cells (H&E stain, original magnification  400).
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